These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22767268)

  • 1. Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogens.
    Cunha BA
    Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):2865-8. PubMed ID: 22767268
    [No Abstract]   [Full Text] [Related]  

  • 2. An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.
    Cunha BA
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):521-6. PubMed ID: 26861814
    [No Abstract]   [Full Text] [Related]  

  • 3. Susceptibility of bacteria from feline and canine urinary tract infections to doxycycline and tetracycline concentrations attained in urine four hours after oral dosage.
    Wilson BJ; Norris JM; Malik R; Martin PA; Wigney DI; Baral RM; Govendir M
    Aust Vet J; 2006; 84(1-2):8-11. PubMed ID: 16498827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections.
    Novelli A; Rosi E
    J Chemother; 2017 Dec; 29(sup1):10-18. PubMed ID: 29271734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infections in cats.
    Litster A; Moss S; Honnery M; Rees B; Edingloh M; Trott D
    J Vet Intern Med; 2007; 21(5):990-5. PubMed ID: 17939554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children.
    Hyun HS; Kim JH; Cho MH; Park E; Ha IS; Cheong HI; Kang HG
    Pediatr Nephrol; 2019 Nov; 34(11):2399-2407. PubMed ID: 31270617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on emerging therapies for urinary tract infections.
    Majeed A; Alarfaj S; Darouiche R; Mohajer M
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):53-62. PubMed ID: 28253831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.
    Mazzariol A; Bazaj A; Cornaglia G
    J Chemother; 2017 Dec; 29(sup1):2-9. PubMed ID: 29271736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for bacterial urinary tract infections.
    Wagenlehner FM; Weidner W; Perletti G; Naber KG
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):375-97. PubMed ID: 20569081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and antibiotic resistance profiles of Gram negative bacilli associated with urinary tract infections (UTIs) in Karachi, Pakistan.
    Rasool MS; Siddiqui F; Ajaz M; Rasool SA
    Pak J Pharm Sci; 2019 Nov; 32(6):2617-2623. PubMed ID: 31969294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar.
    Randrianirina F; Soares JL; Carod JF; Ratsima E; Thonnier V; Combe P; Grosjean P; Talarmin A
    J Antimicrob Chemother; 2007 Feb; 59(2):309-12. PubMed ID: 17138569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gram-negative urinary tract infections and increasing isolation of ESBL-producing or ceftazidime-resistant strains in children: results from a single-centre survey.
    Giardino S; Bandettini R; Perotti M; Piaggio G; Degl'Innocenti L; Sacco R; Ciucci A; Caviglia I; Barabino P; Ginocchio F; Losurdo G; Haupt R; Castagnola E
    Infez Med; 2013 Mar; 21(1):29-33. PubMed ID: 23524898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
    Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
    Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).
    Cantón R; Loza E; Aznar J; Castillo FJ; Cercenado E; Fraile-Ribot PA; González-Romo F; López-Hontangas JL; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
    Rev Esp Quimioter; 2019 Apr; 32(2):145-155. PubMed ID: 30761824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia.
    Assefa A; Asrat D; Woldeamanuel Y; G/Hiwot Y; Abdella A; Melesse T
    Ethiop Med J; 2008 Jul; 46(3):227-35. PubMed ID: 19271386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.
    Marchese A; Gualco L; Debbia EA; Schito GC; Schito AM
    Int J Antimicrob Agents; 2003 Oct; 22 Suppl 2():53-9. PubMed ID: 14527772
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Purnapatre KP; Rao M; Pandya M; Khanna A; Chaira T; Bambal R; Upadhyay DJ; Masuda N
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.